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Background
The causes of poor respiratory function and COPD are incompletely understood, but it is clear that genes and the environment play a role. As DNA methylation is under both genetic and environmental control, we hypothesised that investigation of differential methylation associated with these phenotypes would permit mechanistic insights, and improve prediction of COPD. We investigated genome-wide differential DNA methylation patterns using the recently released 850K Illumina EPIC array in the largest single population sample to date.
Methods
Epigenome-wide association studies (EWASs) of respiratory function and COPD were performed in peripheral blood samples from the Generation Scotland: Scottish Family Health Study (GS:SFHS) cohort (N=3,791; 274 COPD cases and 2,928 controls). In independent COPD incidence data (N=150), significantly differentially methylated sites (DMSs; p<3.6×10 −8 ) were evaluated for their added predictive power when added to a model including clinical variables, age, sex, height and smoking history using receiver operating characteristic analysis. The Lothian Birth Cohort 1936 (LBC1936) was used to replicate association (N=895) and prediction (N=178) results.
Findings
We identified 29 respiratory function and/or COPD associated DMSs, which mapped to genes involved in alternative splicing, JAK-STAT signalling, and axon guidance. In prediction analyses, we observed significant improvement in discrimination between COPD cases and controls (p<0.05) in independent GS:SFHS (p=0.014) and LBC1936 (p=0.018) datasets by adding DMSs to a clinical model.
Interpretation
Identification of novel DMSs has provided insight into the molecular mechanisms regulating respiratory function and aided prediction of COPD risk.
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Research in context
Evidence before this study
We searched for articles in PubMed published in English up to July 25, 2018, with the search terms "DNA methylation" and "respiratory function", or "COPD". We found some evidence for association between differential DNA methylation and both respiratory function and COPD. Of the twelve previous studies identified, eight used peripheral blood samples (sample size [N] range = 100-1,085) and four used lung tissue samples (N range = 24-160).
The number of CpG loci analysed range from 27,578 to 485,512. These studies have not identified consistent changes in methylation, most likely due to a combination of factors including small sample sizes, technical issues, phenotypic definitions, and study design. In addition, no previous study has: analysed a sample from a large single cohort; used the recently released Illumina EPIC array (which assesses ~850,000 CpG loci); adjusted methylation data and phenotype for smoking history, or used both prevalent and incident COPD electronic health record data.
Added value of this study
To our knowledge, this is the largest single cohort epigenome-wide association study (EWAS) of respiratory function and COPD to date (N=3,791). After applying stringent genome-wide significance criteria (P <3.6×10 −8 ), we found that DNA methylation levels at 29 CpG sites in peripheral blood were associated with respiratory function or COPD. Of these 29, seven were testable in an independent population sample: all seven showed consistent direction of effect between the two samples and three showed replication (p<0.007 [0.05/7 CpG sites tested]). Our results suggest that adjustment of both the phenotypic and the DNA methylation probe data for smoking history, which has not been carried out in previous studies, reduces the confounding effects of smoking, identifies larger numbers of associations, and reduces the heterogeneity of effects across smoking strata. We used gene set enrichment and pathway analyses, together with an approach that combines DNA methylation results with gene expression data to provide evidence for enrichment of differentially methylated sites in genes linked to alternative splicing, and JAK-STAT signalling and axon guidance. Finally, we demonstrated that the inclusion of DNA methylation data improves COPD risk prediction over established clinical variables alone in two independent datasets.
Implications of all the available evidence
There is now accumulating evidence that DNA methylation in peripheral blood is associated with respiratory function and COPD.
Our study has shown that DNA methylation levels at 29 CpG sites are robustly associated with respiratory function and COPD, provide mechanistic insights, and can improve prediction of COPD risk. Further studies are warranted to improve understanding of the aetiology of COPD and to assess the utility of DNA methylation profiling in the clinical management of this condition.
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Introduction
Respiratory function is influenced by both environmental factors and genetic factors, with heritability estimates ranging from 39 to 66%. 1, 2 Epigenetic modifications are at the interface of genetics and the environment. DNA methylation, the covalent binding of a methyl group to the 5′ carbon of cytosine-phosphate-guanine (CpG) dinucleotide sequences in the genome, is an epigenetic modification of DNA that is associated with gene expression.
The results of previous epigenome-wide association studies (EWASs) of spirometric measures of respiratory function and respiratory disease have produced inconsistent results, with some identifying significant associations, [3] [4] [5] [6] and others not. [7] [8] [9] Moreover, there has been little consistency between the positive findings reported. 9, 10 Studies of lung tissue 5, 8 have been constrained by sample availability, with the largest study to date comprising 160 subjects. 5 Inconsistency amongst the results of the peripheral bloodbased studies 3, 6, 7, 9, 11 is likely to be due to a number of factors, including small sample size (e.g., two studies had less than 200 samples) 6, 11 and/or investigation of a relatively small number (~27,000) of CpG loci. 3, 11 The study with the largest number of samples (n=1,085) analysed only 27,000 CpG loci, while the largest study using the 450K array (the predecessor to the array used here) analysed 920 samples. 12 Differences in spirometric measures, definitions of COPD, study population characteristics and study design, in particular in the method used to adjust for smoking history, are also likely to be important sources of variation. 9, 10 Here we sought to identify robust associations by assessing methylation in a large single cohort sample, applying a more rigorous correction for smoking history and by performing sensitivity analyses. In contrast to prior studies, we used the recently released Illumina EPIC array, which interrogates over 850,000 methylation sites. All 3,791 individuals in our sample were from a single cohort with extensive and consistent phenotyping comprising clinical investigation, questionnaire, and linkage to routine medical health records. The crosssectional design of prior studies has limited their capacity to distinguish cause and effect. 10 We mitigated this issue by testing our findings for their predictive power in an independent subpopulation of 150 participants with incident COPD who were free of disease at the time of blood sampling. Finally, where data were available, we attempted to replicate our EWAS and prediction findings in an independent cohort, LBC1936, drawn from the same population.
Material and methods
A flow chart showing the overall study design is outlined in figure 1 , and full description of the methods is provided in the appendix.
Epigenome-wide association study
Cohort information
The Generation Scotland Scottish Family Health Study (GS:SFHS) and Lothian Birth Cohort of 1936 (LBC1936) comprise 23,690 and 1,091 participants, respectively. Medical Research Ethics was obtained for all components of GS:SFHS and LBC1936. Written informed consent was obtained from all participants.
Genome-wide methylation profiling
In the GS:SFHS cohort, DNA methylation data was obtained from 5,190 participants using peripheral blood collected at baseline. 13 DNA methylation was assessed using the Infinium MethylationEPIC BeadChip. Quality control procedures were implemented to identify and remove unreliable probes and samples, and probes on the X and Y chromosomes were excluded leaving data for 735,418 methylation loci in 5,190 individuals. In the LBC1936, DNA methylation was assessed in whole blood samples from 1,004 participants using the Illumina HumanMethylation450 BeadChip. Low-quality probes and samples, and probes on the X and Y chromosomes were removed, leaving 450,726 probes and 920 samples for inclusion in the analysis. M-values were calculated for both datasets. The M-values were then pre-corrected for relatedness (in GS:SFHS), array processing batch and estimated cell counts.
Trait data
Respiratory function was assessed at the time of blood sampling in 4,193 GS:SFHS and 895 LBC1936 participants with methylation data. Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured in litres, using spirometry. Quality control of the phenotype data was undertaken to exclude participants with inaccurate spirometry or covariate data; 4,171 and 895 individuals were retained in the GS:SFHS and LBC1936 samples respectively.
Following the Global Initiative for Obstructive Lung Disease (GOLD) criteria, participants
with predicted FEV1 (from NHANES III equations) <80% and FEV1/FVC <0.7 were classified as COPD case subjects. 14 Individuals with FEV1 >80% predicted and FEV1/FVC >0.7 were classified as control subjects.
The GS:SFHS dataset (N=4,171) was then divided into an incident COPD dataset (i.e., where COPD developed after recruitment to the cohort) for prediction analysis and a discovery EWAS dataset. The prediction dataset (described below) comprised of incident COPD cases and matched controls. To ensure independence, individuals in the prediction sample and their close relatives (identity by state [IBS]>0.05) were not included in the discovery dataset; leaving 3,791 for inclusion in the EWAS analysis.
Identification of differentially methylated sites (DMSs)
FEV1, FVC, FEV1/FVC, and COPD phenotypic data were pre-corrected for age, age 2 , sex, height, height 2 , smoking status (current smoker, former smoker [< 12 months], former smoker [≥ 12 months], and never smoked), and pack-years. FVC data was additionally precorrected for weight. Linear regression models were run in the limma package in R, fitting each CpG site (corrected M-values) as the dependent variable, and respiratory function traits or COPD, age, sex, smoking status, pack-years and the first 20 principal components from the corrected M-values. The genome-wide significance threshold was set at 3.6×10 −8 . 15 
Sensitivity analyses
To assess the impact of pre-correction of the traits for smoking history, we undertook sensitivity analyses, in which FEV1, FVC, FEV1/FVC, and COPD were not pre-corrected for smoking status and pack-years. To assess the generalisability of the estimated effects in older adults and according to smoking status (ever smokers and non-smokers), the data was censored by age (>40 years; an age group with greater risk of COPD 14 ) and stratified by smoking status. For each set of analyses, we conducted separate random-effects metaanalyses using the metafor package in R for each trait-specific genome-wide significant DMS.
Probe annotation and epigenetic regulation of gene expression
DNA methylation probes were mapped to genes based on the IlluminaHumanMethylationEPICanno.ilm10b2.hg19 library. For each trait, methylation probes were filtered at p<0.001, and probes that mapped to genes extracted. The Benjamini Hochberg, False Discovery Rate method, was used to correct for multipletesting with p<0.05 being considered significant. We used the Significance-based Modules Integrating the Transcriptome and Epigenome (SMITE) package in R to combine summary statistics from publicly available COPD lung gene expression data 16 with methylation results from this study. Trait-specific gene modules (set of genes with shared regulation; p<0.05 and 10-500 genes) were then identified and subjected to KEGG pathway enrichment analysis and terms with a p<0.05 were held as significant. As hospital admission data were not available for the LBC1936 cohort, spirometry data were used to define case-control status. In total, 89 participants with DNA methylation data had prevalent COPD [GOLD stage ≥2 cases]. Controls were selected at random from the participants with DNA methylation data in a 1:1 ratio to case participants. This dataset was used to replicate the prediction findings from GS:SFHS.
Model selection
For the training data, the reduced model, including clinical risk factors, age, age 2 , sex, height, height 2 , smoking status (current, former and never), and pack-years of smoking 6 was constructed using unpenalized logistic regression. The full model, including DMSs and clinical risk factors, was constructed using penalized logistic regression with an elastic net penalty. Selection of the full model was conducted based on 10-fold cross-validation (appendix p28) using the R package caret. The optimal model was selected based on the maximum mean area under the curve (AUC). Final models were constructed using the complete training set and evaluated on the independent test and replication datasets.
Model evaluation
Comparison of the predictive performance of the models was carried out using the AUC in the pROC R package. The incremental value of the DMS to predict COPD risk, when added to the model with established clinical predictors was assessed using the integrated discrimination improvement (IDI), and binary net reclassification improvement (NRI) measure. Finally, we performed decision curve analysis to estimate the potential clinical usefulness of the models in the 'rmda' R package.
Results
EWAS sample characteristics
The discovery sample for respiratory function traits comprised 3,791 individuals from GS:SFHS. For the COPD analysis, there were 274 cases and 2,928 controls (table 1; figure   1 ).
Differentially methylated sites
EWASs for the three respiratory function traits (FEV1, FVC and FEV1/FVC) and COPD on the discovery data identified 30 genome-wide significant associations (p<3.6×10 −8 ; Eleven of the 26 genes that contain DMSs have previously been implicated by genetic, EWAS and functional analysis in respiratory function or disease (excluding cancer; appendix p8-9). Three FEV1 related-DMSs mapped to the SOCS3 gene (table 2); DNA methylation levels at these sites are highly correlated (appendix p30).
We next attempted to replicate these findings in 895 individuals from the LBC1936 (appendix p10). No other Illumina EPIC dataset was available, but seven of the 29 DMSs identified in the discovery dataset had been profiled using the HumanMethylation450 BeadChip, which had been applied to the LBC1936. Of these seven, two FEV1-associated DMSs (cg18181703 in SOCS3 and cg18608055 in SBNO2) and one FEV1/FVC ratioassociated DMS (cg03636183 in F2RL3) replicated in LBC1936 (Bonferroni-corrected p≤0.00714). For all seven probes, however, the direction of the effects were the same in the two datasets (appendix p11).
Sensitivity analyses
As age and smoking affect both DNA methylation and lung function, 17, 18 we undertook sensitivity analyses for each significant DMS for each trait. The associations between each significant DMS and its associated phenotype were assessed in older adults (>40) and smoking strata (ever smokers and non-smokers). Meta-analysis was used to compare regression coefficients from the discovery dataset and the sensitivity analyses. All but three of the associations identified in the discovery dataset were robust to differences in age and smoking status (p<0.05/30 DMSs; appendix p12-13). The association between FVC and cg00213822 in OFCC1 was primarily driven by non-smokers, whereas, the associations with FEV1/FVC and the established smoking-associated DMSs, cg05575921, in AHHR, and cg03636183, in F2RL3, were primarily driven by smokers (appendix p31).
We carried out sensitivity analyses in which the trait data were not pre-corrected for smoking history (appendix p14-17). Three of the identified associations were affected by pre-correction of the traits (appendix p17 & 32). In addition, an FVC-related DMS was identified at cg03187361 only when the trait data was not pre-corrected for smoking history. Pre-correction for smoking history substantially reduced the heterogeneity of the effect size estimates of the association between COPD and DNA methylation at cg09455379 and cg02743991 across the age and smoking strata. This strengthened associations, which attained genome-wide significance.
Gene ontology analysis
For each trait, to explore whether genes with DMSs share functional features, we filtered methylation probes at p<0.001 and performed biological processes (appendix p33), molecular function (appendix p34) and canonical pathway enrichment analyses (appendix p18-25). In the study of molecular functions, we found that each of the four traits were significantly enriched for genes linked to the alternative splicing and phosphoprotein categories (appendix p34), while DMSs associated with FEV1 and COPD showed enrichment for "cytoplasm organization and biogenesis", and "disease mutation" respectively (appendix p34). Many of the canonical pathways identified were related to signalling, including apoptosis (appendix p18), cardiovascular signalling (appendix p20) and neurotransmission (appendix p25).
Integrative analysis of methylation and expression
To investigate the functional relevance of the methylation changes, we integrated transcriptional (COPD case-control differential expression in lung tissue) 16 and epigenetic (from this study) datasets to identify functional gene modules for the traits under study. This analysis identified two significant modules (p<0.05) containing 27 and 34 genes with correlated differential methylation associated with FEV1 and expression in COPD, respectively (appendix p26, p35-36). DMSs mapped to two genes SIAH2 and NEO1 in module 1 (appendix p35) and SOCS3 in module 10 (appendix p36). Gene enrichment analysis revealed that the top pathway for module 1 was axon guidance, while the top pathways for module 10 were cytokine-cytokine receptor interaction and JAK-STAT signalling (p<0.05; appendix p26). No significant functional gene modules were identified for the other phenotypes.
Predictive value of the DMS
To determine the predictive value of DMSs in the prognosis of COPD, we used an independent training and test set design to predict COPD risk in GS:SFHS and LBC1936. We 
Discussion
We performed EWASs of three respiratory function traits and COPD in DNA extracted from peripheral blood using the high-density Illumina EPIC array, in 3,471 individuals from a single cohort. These analyses identified 29 DMSs (28 novel), of which 26 are associated with respiratory function and three with COPD in the discovery GS:SFHS data. Data were available to test seven of the 29 DMSs for replication in an independent dataset; three associations replicated. Adjustment of both the phenotypic and DNA methylation data for smoking history appeared to reduce the confounding effects of smoking, identify more associations, and reduce the heterogeneity of effect estimates across smoking strata.
Incorporation of a subset of the identified DMSs into a model composed of established clinical variables improved discrimination of individuals at-risk of COPD in two independent samples. Finally, functional annotation provided insights into the biology of these phenotypes.
Eleven of the 26 genes that contain DMSs have been previously linked to respiratory function or disease (appendix p8-9). In four cases, these links come from studies in lung tissue: DNA methylation changes in ABCA1 in lung tissue has been reported to be associated with pulmonary arterial hypertension; differential expression of ABCA1 and DNAH9 has been reported in lung tissue of patients with COPD and primary ciliary dyskinesia respectively and pathological changes in lung tissue have been reported following knockdown and knockout of SLAMF7, ABCA1, and SOCS3.
Three DMSs showed replication. The first, cg18181703, is one of three FEV1-associated DMS in SOCS3, which modulates the lung inflammatory response, 19 and JAK-STAT signal transduction. 20 Transcriptional down-regulation of SOCS3 has been observed in COPD patients. 21 Differentially methylated sites in SOCS3 within a FEV1-related gene module in this study were correlated with differential gene expression in lung tissue of COPD patients. 16 A DMS in SOCS3 was the third most predictive DMS in the prognostic model for COPD in the GS:SFHS cohort. Inclusion of this DMS in the prediction model also improved the prediction of prevalent COPD risk in the LBC1936.
The second replicated DMS, cg18608055, is a FEV1-associated DMS in SBNO2, which encodes a transcriptional co-regulator of the pro-inflammatory cascade. 22 The third, cg03636183, is a FEV1/FVC ratio-associated DMS in F2RL3, which has been previously reported to be associated with respiratory function. 3 This DMS was also the most informative DMS in the prediction model for COPD in an independent GS:SFHS prediction dataset, and also in the LBC1936 replication data.
As discussed above, SOCS3 and F2RL3 were found to provide discriminatory power in the prediction analysis. The inclusion of three other DMSs in RALGDS, JADE1 and SIAH2 improved the prediction of incident COPD risk in the GS:SFHS. JADE1 is a negative regulator of Wnt signalling, which has been linked to the pathogenesis and progression of COPD. 23 RALGDS is a Ras effector and regulates cellular processes such as vesicular trafficking, endocytosis, and migration. 24 SIAH2 upregulation mediates the ubiquitination of NRF2 which has been previously associated with respiratory function 25 and COPD. 26 Functional annotation of differently methylated genes identified enrichment of the molecular function alternative splicing (appendix p43). This finding is consistent with earlier reports that genes associated with COPD (unlike those associated with other complex traits examined) have greater transcriptional complexity due to a disproportionately high level of alternative splicing. 27 In addition, many such genes are spliced differently in COPD patients and controls. 27 Functional analysis also identified two cellular pathways (appendix p43). JAK-STAT signalling (appendix p44) was highlighted in the EWAS data at both the DMS level and in the gene ontology analysis. Inclusion of a SOCS3 DMS in the model improved the prediction of COPD in independent datasets. Finally, one of the modules comprising genes that showed both differential methylation with FEV1 in this study, and COPD-based gene expression in lung tissue 16 was enriched for JAK-STAT signalling genes. Thus our data add further support to previous evidence 28 for the importance of this pathway in respiratory function and COPD.
Finally, axon guidance signalling (appendix p45) was highlighted by three of our analyses, adding support to the neuropathology hypothesis of COPD. 29 To investigate the potential clinical implications of our findings we assessed the predictive properties of DMSs in the prognosis of COPD. The inclusion of DMSs provided added clinical value to established clinical variables in both the discovery and replication datasets.
Clinical studies are needed to provide formal proof that changes in DNA methylation at these sites contribute causally to the pathogenesis, and can impact prognosis of COPD.
There are two main limitations to this study. Firstly, DNA methylation was quantified in peripheral blood. There is ongoing debate about whether DNA methylation from peripheral blood can serve as a surrogate marker for DNA methylation in lung tissue. 30 The overlap between our findings and previous studies performed in lung tissue (appendix p8-9) suggest that, for at least some loci, the study of DNA methylation in blood may yield mechanistic insights. Moreover, our data demonstrate that DMSs from peripheral blood have both predictive and clinical value. As such, blood may be an appropriate tissue for the development of biomarkers, as it is easily and repeatedly accessible.
The second limitation is that DNA methylation was measured in blood samples collected at the same time that spirometry tests were performed. As such, our reported associations are subject to reverse causality. However, the integrated alterations in DNA methylation in this study and gene expression profiles in COPD 16 and prospective predictive value of the selected DMSs provide indications that the DNA methylation alterations observed in blood may play a causal role in respiratory function. Nevertheless, longitudinal studies, with serial measurements of DNA methylation will be required to address causality formally.
In conclusion, using a large dataset and a robust methodological approach, we have identified DMSs associated with respiratory function and COPD, provided new mechanistic insights and supported previous hypotheses into impaired respiratory function and the pathogenesis of COPD. We also demonstrated that DMSs can be incorporated into existing models for predicting COPD risk, yielding better prediction than established clinical variables alone. participants (n= 3,791) in the epigenome-wide association study discovery population. Table 2 . Genome-wide significant differentially methylated sites (DMSs) associated with the respiratory function traits or chronic obstructive pulmonary disease (COPD) in the Generation Scotland Scottish Family Health Study (GS:SFHS) discovery data. Results are ordered by chromosomal location. Table 1 . Characteristics of Generation Scotland: Scottish Family Health Survey (GS:SFHS) participants (n= 3,791) in the epigenome-wide association study discovery population. Table 2 . Genome-wide significant differentially methylated sites (DMSs) associated with the respiratory function traits or chronic obstructive pulmonary disease (COPD) in the Generation Scotland Scottish Family Health Study (GS:SFHS) discovery data. Results are ordered by chromosomal location.
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